Compare FBIO & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBIO | CCIF |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | 101 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.6M | 84.8M |
| IPO Year | N/A | N/A |
| Metric | FBIO | CCIF |
|---|---|---|
| Price | $2.55 | $3.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 416.9K | 126.5K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 25.90% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.71 | N/A |
| Revenue Next Year | $49.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $3.01 |
| 52 Week High | $4.53 | $7.13 |
| Indicator | FBIO | CCIF |
|---|---|---|
| Relative Strength Index (RSI) | 32.50 | 45.38 |
| Support Level | $2.47 | $3.24 |
| Resistance Level | $2.71 | $3.60 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 17.37 | 80.65 |
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.